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INTRODUCTION
High-dose therapy with hematopoietic cell support has
been widely used in patients with a variety of hematolym-
phoid diseases [1,2]. Autologous transplantation has been
pursued in patients with breast cancer in both the high-risk
and the metastatic setting [3,4]. One randomized clinical
trial in patients with re c u rrent or metastatic breast cancer
suggested benefit for those patients who received a double-
transplant approach compared with patients receiving con-
ventional chemotherapy [5]. However, a recently re p o rt e d
l a rger randomized clinical trial has failed to show a surv i v a l
benefit [6]. Randomized clinical trials are under way to
d e t e rmine the potential benefit of this treatment modality
in stage II or III breast cancer patients at high risk for
relapse. A concern with the use of autologous bone marro w
and, more re c e n t l y, with “mobilized” peripheral blood pro-
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ABSTRACT
We re p o rt here the transplantation of extensively purified “mobilized” peripheral blood CD34+T h y - 1+ h e m a t o p o i e t i c
stem cells from 22 patients with re c u rrent or metastatic breast cancer. Patients were mobilized with either high-dose
granulocyte colony-stimulating factor (G-CSF) alone or cyclophosphamide plus G-CSF. Median purity of the stem cell
p roduct at cry o p re s e rvation was 95.3% (range, 91.1%-98.3%), and viability was 98.6% (range, 96.5%-100%). After
high-dose chemotherapy with carmustine, cisplatin, and cyclophosphamide, CD34+T h y - 1+ cells at a median dose of
11.3 × 1 05 per kilogram (range, 4.7-163 × 1 05 per kilogram) were infused. No infusion-related toxicity was observ e d .
N e u t rophil re c o v e ry was prompt, with median absolute neutrophil count >500/mL by day 10 (range, 8-15 days) and
> 1 0 0 0 /mL by day 11 (range, 8-17 days). Median platelet re c o v e ry (>20,000/mL) was observed by day 14 (range,
9-42 days) and >50,000/mL by day 17 (range, 11-49 days). Tumor cell depletion below the limits of detection of a sen-
sitive immunoflu o rescence-based assay was accomplished in all patients who had detectable tumor cells in aphere s i s
p roducts before processing. Although CD4+ T-cell reconstitution was slow, no unusual infections were observed. Nei-
ther early nor late graft failure was observed, and no patient re q u i red infusion of unmanipulated backup cells. At a
median follow-up of approximately 1.4 years and a maximum follow-up of 2.5 years, 16 of the 22 patients remain alive,
with 9 free of disease pro g ression, and have stable blood counts. In summary, highly purified CD34+T h y - 1+ cells used
as the sole source of the hematopoietic graft result in rapid and sustained hematopoietic engraftment.
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genitor cells (PBPCs) has been the possibility that occult
clonogenic tumor cells contaminating the pro duct could
contribute to relapse after transplantation. Gene-mark i n g
techniques have confirmed that malignant cells can be
t r a n s f e rred during an autologous transplant pro c e d u re
[7,8]. A number of approaches, including chemical and
immunologic treatments, have been developed in an eff o rt
to deplete stem cell products of tumor cells [9,10]. An
a l t e rnative strategy is to positively select for hematopoietic
stem cells, thereby depleting unwanted tumor cells. This
strategy would theoretically be effective in a broad array of
diseases in which the potentially contaminating tumor cells
tested negative for the markers used to select the hemato-
poietic stem cells (HSCs).
The use of mobilized PBPCs in autologous transplanta-
tion has resulted in rapid, stable long-term engraftment
[11,12]. The rapidity of engraftment has correlated with the
C D 3 4+ cell content of the graft such that a dose of >2.0 × 1 06
C D 3 4+ cells per kilogram has resulted in rapid hemato-
poietic recovery [10,13-15]. CD34+ cells make up a minority
population of cells in PBPC grafts, and within the CD34+
cell population, considerable heterogeneity exists [16,17].
A number of investigators have identified other markers
associated with the phenotype of hematopoietic stem cells,
as compared with more committed progenitor cells. In
murine systems, the coexpression of Thy-1 and a second
antigen, termed stem cell antigen-1 (SCA-1), and the absence
of diff e rentiation markers typically observed on mature
B cells, T cells, granulocytes, macrophages, and ery t h ro i d
cells (Lin−) have defined a stem cell phenotype capable of
rescuing lethally irradiated mice [18]. Secondary transfer
experiments have further defined this population of cells as
stem cells capable of sustained multilineage repopulation of
lethally irradiated animals [19]. Other markers, including
e x p ression of the c-k i t receptor [20] and the capability of
excluding the dye rhodamine [21-24], have also defined
immature populations of human and murine stem cells.
There has been considerable debate as to the source of
cells responsible for early and late hematopoietic reconstitu-
tion after transplantation. Some investigators have arg u e d
that committed hematopoietic progenitor cells are responsi-
ble for the initial wave of hematopoietic reconstitution, fol-
lowed by engraftment of the most immature population of
stem cells, which in turn are responsible for sustained multi-
lineage engraftment. Others have argued that only imma-
t u re hematopoietic stem cells are re q u i red, as suff i c i e n t
numbers of highly purified SCA-1+Thy-1+Lin− murine stem
cells engraft with kinetics identical to those of whole
bone m a rrow [25]. High doses (>2.5 × 1 05/kg) of c-kit+
SCA-1+Thy-1+Lin− murine stem cells, and even the Rh123lo
subset, can give rise to rapid (<11 days) engraftment of neu-
trophils and platelets [24].
In humans it has been more difficult to define markers
present on the most immature hematopoietic stem cells, as
assay systems are complex and there is no universal agre ement
on which in vitro or in vivo assays best define populations of
cells capable of multilineage, long-term hematopoietic
engraftment. A variety of markers have been used to frac-
tionate the CD34+ cell population, including Thy-1 [26,27],
CD38 [28], and HLA-DR [29,30]. In addition, there is evi-
dence for an immature population of CD34– cells capable of
multilineage engraftment in mice with severe combined
immunodeficiency (SCID) [31].
A number of investigators have defined a population of
human cells with stem cell pro p e rties that have the cell surf a c e
phenotype of CD34+T h y - 1+L i n− [26,27,32]. CD34+T h y-1+
L i n− stem cells are found at increased frequency in peripheral
blood after mobilization [33,34]. Highly selected CD34+T h y -
1+L i n− cells demonstrate multilineage potential according to
in vitro and in vivo assays in SCID mice and in utero sheep
models [26,32]. 
To evaluate the ability of highly purified CD34+T h y - 1+
stem cells to engraft in patients, we perf o rmed a phase 1/2
s t u d y in patients with metastatic breast cancer. The goals of
the study were to determine the feasibility of isolating suffi-
cient numbers of extensively purified CD34+Thy-1+ cells by
high-speed fluorescence-activated cell sorting, to evaluate
the degree of tumor cell depletion, and to determine the
engraftment potential of these cells in patients undergoing
high-dose therapy for recurrent or metastatic breast cancer. 
PATIENTS AND METHODS
Pa t i e n t s
Patients with recurrent or metastatic breast cancer who
were between the ages of 19 and 70 years were eligible for
this trial. Patients were re q u i red to have a histologically
c o n f i rmed diagnosis of breast cancer and to have re c e i v e d
<6 months of chemotherapy since the diagnosis of metasta-
tic disease. Patients who had previously received >400 mg/m2
of anthracycline were excluded. Each patient’s primary
b reast cancer cells were screened for CD34 expression; if
results were positive, the patient was excluded from the
study. Adequate performance status (Karnofsky perform a n c e
s c o re >70%), renal function (serum creatinine <1.5 mg/dL),
pulmonary function (forced vital capacity [FVC] >50% and
p u l m o n a ry diffusing capacity >50% of predicted), card i a c
function (ejection fraction >45%) and liver function (serum
b i l i rubin <2.5 times the upper limits of normal) were
re q u i red. Patients with central nervous system (CNS) dis-
ease were excluded. Results of serologic tests for hepatitis B
and C and human immunodeficiency virus (HIV) were
re q u i red to be negative. All patients signed informed con-
sent forms approved by the Institutional Review Boards of
either Stanford University Hospital (Palo Alto, CA) or the
Barbara Ann Karmanos Cancer Institute (Detroit, MI).
S c r eening Studies
B e f o re mobilization, eligible patients were re q u i red to
have an absolute neutrophil count (ANC) >1500/µL; a
platelet count >120,000/µL; a negative chest x-ray; a nega-
tive computed tomography (CT) or magnetic re s o n a n c e
imaging scan of the brain; a diagnostic CT evaluation of the
chest, abdomen, and pelvis; and a radionuclide whole-body
bone scan. For quantification of tumor cell involvement,
diagnostic bone marrow aspiration and biopsy specimens
were evaluated morphologically and with the use of a sensi-
tive immunofluorescence-based assay.
M o b i l i z a t i o n
Two mobilization strategies were used. The first cohort
of patients (n = 15) received granulocyte colony-stimulating
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factor (G-CSF) (Neupogen; Amgen, Thousand Oaks, CA)
at a dosage of 24 µg/kg per day based on actual body weight.
A second cohort of 13 patients received cyclophosphamide
(4 gm/m2, based on adjusted ideal body weight) plus G-CSF
(10 µg/kg per day). For patients who received G-CSF alone,
apheresis was begun on day 4 and continued on a daily basis
for a maximum of 4 aphereses or until adequate purified
stem cell yields and backup of unselected cells were obtained
as described below. For patients who received cyclophos-
phamide and G-CSF, apheresis was initiated when the white
blood cell (WBC) count reached 1000/µL on recovery from
the nadir.
Stem Cell Isolation and Cry o p re s e rv a t i o n
Mononuclear cells collected by apheresis were diluted
to a final concentration of <5 × 1 07 cells/mL in pro p r i e t a ry
t r a n s p o rt medium before shipment to SyStemix (Palo Alto,
CA). At SyStemix, each patient’s samples were analyzed for
cell number, viability, and phenotype and were either
p rocessed immediately or held overnight at room tempera-
t u re. CD34+ T h y - 1+ HSCs were purified using the Isolex
( B a x t e r, Irvine, CA) immunomagnetic positive selection
device [35] to enrich for CD34+ cells and subsequent high-
speed flow-cytometric cell sorting for the final purification
of CD34+T h y - 1+ HSCs. 
The immunomagnetic CD34 selection process consisted
of four steps: (1) labeling cells with an anti-CD34 monoclo-
nal antibody (MAb); (2) mixing cells with paramagnetic
beads coated with sheep antimouse immunoglobulin G
(IgG), whereby CD34+ cells form rosettes with the beads;
(3) attaching the rosettes to a magnet and washing CD34−
cells from the system; and (4) releasing the cells from the
beads using a peptide mimotope that competes with the
MAb binding site of the CD34 molecule. Residual erythro-
cytes, if any, were lysed with 150 mmol/L ammonium
c h l oride lysis buff e r, pH 7.5, for 5 minutes at 4°C. Before
staining, the cells were incubated with 0.1% human
immunoglobulin (Gammimune; Bayer, Berkeley, CA) for 10
minutes at 4°C to block nonspecific binding. The cells were
stained at a concentration of 2 × 107 cells/mL for 20 minutes
at 4°C with SyStemix-manufactured MAbs that re c o g n i z e
CD34 and Thy-1 antigens (2.5 µg/mL CD34 sulforh o-
damine [SRG], 2.5 µg/mL Thy-1 Biotin). SyStemix’s flu o-
resceinated anti-CD34 MAb was directed against a different
epitope of CD34 from that of the antibody used in the
immunomagnetic selection device. Without washing, strep-
tavidin (Societa Prodotti Antibiotici, Milano, Italy) was
added to the cells at a final concentration of 0.15 mg/mL
and incubated for an additional 20 minutes. Cells were
washed twice in cold phosphate-buffered saline (PBS) with
1% human serum albumin (HSA) (Alpha Therapeutics, Los
Angeles, CA), resuspended to 2 × 107 cells/mL in 5 µg/mL
phycoerythrin (PE)-biotin (SyStemix) and incubated for 20
minutes at 4°C. In preparation for sorting, the cells were
washed once with cold PBS/1% HSA, resuspended to 2 ×
107 cells/mL in PBS/1% HSA plus 100 U/mL deoxyribonu-
clease (DNAse) (Benzonase; Nycomed, Copenhagen, Den-
mark), and kept at a temperature of 2°C to 8°C.
The HSCs were sorted as previously described using
S y S t e m i x ’s pro p r i e t a ry dual-laser, fluore s c e n c e - a c t i v a t e d ,
high-speed clinical cell sorter [36]. PE was excited by an
argon laser emitting 488 nm light, and SRG was excited by a
rhodamine 6-G dye laser emitting 590 nm light. Forward-
and side-scatter sort windows were set to exclude very small
or very large cells and cell clusters. Selection criteria for
CD34 were based on the fluorescence of unstained cells
(autofluorescence), and the selection criteria for Thy-1 (PE)
were based on the background fluorescence of cells stained
with anti−T h y - 1−biotin and biotin-PE but lacking stre p t-
avidin. Cells were sorted at a rate of 15,000 to 20,000 events
per second. The CD34+T h y - 1+ cells were sorted dire c t l y
into a culture tube containing a small volume of SyStemix’s
proprietary culture medium and were stored at a tempera-
ture of 2°C to 8°C until cryopreservation. 
C ry o p re s e rvation. The purified HSCs were washed fre e
of s o rter sheath fluid, counted with a hemacytometer, and
resuspended to a maximum of 4 × 1 07 cells/mL in SySt e m i x -
m a n u f a c t u red pro p r i e t a ry cry o p re s e rvation medium
cont a i ning 2% hetastarch, 4% HSA, and 7.5% dimethyl sul-
foxide (DMSO) as cry o p rotectants. The cells were divided
into aliquots and placed into 2 or more cryovials. Cells were
frozen using a programmable step-down freezer (Cryomed
#110; Forma Scientific, Marietta, OH) with a freezing pro-
file previously optimized for HSC survival. The step-down
f reezer was programmed to freeze at −1°C/min until the
sample reached a temperature of −45°C, and then to freeze
at −1 0°C/min until the sample reached a temperat u re of 
−1 4 0°C. After the product temperature reached −140°C,
the vials were transferred to the liquid phase of a liquid
n i t rogen cryostorage tank. Once the target dose was
achieved and all products were released, the HSC infusion
products were shipped to the clinical site in a liquid nitro-
gen shipper (CP65; Taylor-Wharton Scientific, Harrisburg,
PA) and returned to the liquid phase of liquid nitrogen until
the time of infusion. 
Reserve backup cells. All patients had a backup collection of
unmanipulated cells of either >1 × 1 08 mononuclear cells
per kilogram or >1.2 × 106 CD34+ cells per kilogram, which
were cryopreserved and maintained at each clinical site.
I m mu n o f l u o r escence Assay of Minimal Residual
D i s e a s e
A sensitive immunofluorescence-based assay was used to
detect and quantify breast cancer cell contamination of bone
m a rro w, apheresis products, and subsets of purified cells.
For products with extensive red blood cell contamination,
red cell lysis was performed with NH4Cl solution. The cells
w e re then resuspended in normal rabbit serum (10%) in
D u l b e c c o ’s phosphate-buff e red saline (DPBS). After an
incubation period of 30 minutes on ice, anti-CD34 antibody
(9C5) was added at a concentration of 1 µg/106 cells. After
another 30 minutes of incubation at 0°C, the cells were
resuspended in normal rabbit serum (10%) in DPBS and the
secondary antibody (goat antimouse; Texas Red–conjugated)
was added at a concentration of 250 ng/106 cells. After an
additional 30 minutes of incubation (0°C, dark conditions),
the cells were fixed in 1% paraformaldehyde for 30 to 60 min-
utes. Cytospins were then pre p a red using precoated slides
(Shandon, Pittsburgh, PA) and cytofunnels (appro x i m a t e l y
1 × 1 05 cells/slide). The cells were fixed in methanol−a c etone
(3:1) for 5 minutes at −20°C. After thorough washing in
deionized water and permeabilizing, 50 µL of normal rabbit
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s e rum (10%) was added to the slide and a cover slip was
carefully layered to minimize evaporation. A moist dark box
was used for all subsequent incubations. Cytokeratin cock-
tail antibodies (CAM 5.2-FITC and KL1-FITC/
2 . 5 µg/mL; 50 µL/slide) were then added and the slides
incubated for an additional 30 minutes. The cells were
counterstained with Dapi (33 ng/mL; 100 µL/slide). After
air drying, each slide was mounted in 7 µL antifade mount-
ing media (VectaShield). Single-positive (green) and double-
positive (green plus red) cells were analyzed using a Zeiss
Axioplan fluorescent microscope (Carl Zeiss, Thorn w o o d ,
NY) with Texas Red/FITC filters.
High-Dose Therapy and Stem Cell Infusion
Patients were prepared for high-dose therapy with vig-
orous hydration using 5% dextrose plus normal saline with
20 mEq/L KCl at 250 mL/h starting 12 hours before t h e
administration of chemotherapy. Patients received allopuri-
nol 300 mg/d and intravenous trimethoprim-sulfamethazole
for 5 days. Starting on day −6 before the stem cell infusion,
cisplatin (cDDP) at a dosage of 55 mg/m2 per day was
administered by continuous infusion for a total of 72 hours.
Cyclophosphamide (CPA) at a dosage of 1875 mg/m2 p e r
day was infused over 1 hour on days −6, −5, and −4. Urine
output was maintained at more than 200 mL/h by forc e d
d i u resis with intravenous (IV) fluid and mannitol or
f u rosemide as re q u i red. On day −3, carmustine at 600 mg/m2
per day was infused over 2 hours [37]. Adequate antiemetics
were administered. On the day of stem cell infusion (day 0),
the cry o p re s e rved purified hematopoietic stem cells were
rapidly thawed, diluted in SyStemix pro p r i e t a ry medium,
and administered to the patient by rapid IV push through a
syringe. G-CSF was begun on day 0 at a dosage of 5 µg/kg
per day and continued until the ANC exceeded 2000/µL for
4 consecutive days. Red blood cells were infused for hemat-
ocrit levels of <30%, and platelets were transfused for
platelet counts of <10,000/µL or as clinically indicated. All
blood products other than the purified HSCs were irr a d i-
ated with 2500 cGy before infusion. Patient follow-up
included daily blood counts until re c o v e ry and then twice
weekly until day 60. Peripheral blood absolute numbers of
C D 3+, CD4+, and CD8+ T cells were determined by flow
cytometry on days 14, 28, 60, and 100. 
Definition of Engraftment
N e u t rophil engraftment was defined as the first days
posttransplantation that the ANC exceeded 500/µL and then
1 0 0 0 /µL. Platelet engraftment was defined as the first days
an unsupported platelet count exceeded 20,000/µL and then
5 0 , 0 0 0 /µL. Backup unmanipulated PBPCs could be infused
as early as day 21 if engraftment had not occurred and were
re q u i red to be infused on day 28 if an ANC >500/µL had not
been achieved. Antibiotics and antiviral and antifungal agents
w e re administered according to institutional practice. 
Statistical Anal y s i s
The Fisher exact test was used to evaluate P values for
comparing mobilization efficiency and tumor cell conta-
m i n a t i o n .
RESULTS
Patient Characteristics and Stem Cell Collection
Twenty-eight patients were enrolled in this study; clini-
cal characteristics are shown in Table 1. All of the patients
were women with recurrent or metastatic breast cancer. The
median age was 46 years (range, 34-59 years). Tw e n t y
patients had a previous history of breast cancer that pro-
g ressed to metastatic disease, and 8 patients had an initial
p resentation of metastatic breast cancer. The sites of
metastatic disease included bone, bone marrow, viscera, and
lymph nodes. Two additional patients were evaluated for the
study but were excluded owing to expression of CD34 on
cytokeratin-positive breast cancer cells. All patients had
chemotherapy-sensitive disease and were treated with adri-
amycin, taxol-containing regimens, or both. Six patients
failed to proceed to transplantation. Four patients failed to
mobilize adequately for stem cell selection and underw e n t
transplantation off protocol with unmanipulated PBPCs.
Two patients developed early relapses between mobilization
and the scheduled transplantation. 
The first 15 patients were mobilized with G-CSF alone
at a dose of 24 µg/kg per day (Table 2). This dose was chosen
in an eff o rt to improve the mobilization re q u i red to obtain
s u fficient CD34+ cells for cell sorting. Three patients (20%)
failed to mobilize adequately, whereas 12 patients achieved
an adequate CD34+T h y - 1+ cell dose and went on to trans-
plantation. Because of these mobilization failures, a second
c o h o rt of 13 patients received cyclophosphamide (4 gm/m2)
followed by G-CSF (10 µg/kg per day). One patient (7.7%)
in this cohort did not have adequate mobilization to pro c e e d
to stem cell isolation (P = .6). Two patients suff e red pro g re s-
sive growth of their disease after mobilization and did not
p roceed to transplantation. Ten patients in this second
c o h o rt achieved an adequate CD34+T h y - 1+ stem cell dose
and proceeded to high-dose therapy and transplantation.
Table 1. Patient characteristics*
No. of patients 28
Sex
Male 00
Female 28
Median age (years) 46 (range, 34-59)
Breast cancer stage at diagnosis
I 03
II 12
III 05
IV 08
Breast cancer stage at time of transplantation
IV 28
Mobilization regimen
G-CSF (24 mg/kg per day) 15
Cyclophosphamide (4 gm/m 2) 13
+ G-CSF (10 mg/kg per day)
Reasons for failing to proceed to transplantation
Inadequate mobilization 04
Early relapse 02
No. of patients who underwent transplantation 22
*Data are n. G-CSF indicates granulocyte colony-stimulating factor.
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A minimum of 2 apheresis products were used for
C D 3 4+T h y - 1+ stem cell isolation by protocol design. Addi-
tional apheresis products were obtained for backup and were
c ry o p re s e rved without further manipulation. In the initial
a p h e resis products, the median CD34+ cell percentage was
0.49% (range, 0.11%-3.66%), and 64.1% of the CD34+ c e l l s
(range, 44.3%-82.4%) were positive for Thy-1. However,
because of the low frequency of cells staining positive for
these markers, this value may lack accuracy. After CD34+ c e l l
selection, the median purity of the cells was 86.8% (range,
5%-97.9%). The purity of the CD34+T h y - 1+ cells after sort-
ing exceeded 90% in all cases with a median of 95.3% (range,
Figure 1. Time to engraftment of neutrophils (>500/µL) and platelets (>20,000/µL) after transplantation with purified CD34+Thy-1+ hematopoietic stem cells. 
Table 2.
Engraftment and Follow-up of Patients Undergoing Transplantation With Purified CD34+Thy-1+ Stem Cells*
Mobilization No. of CD34 +Thy-1 + Viability Purity ANC ANC Platelets Platelets Relapse Status
Patient Site Regimen Aphereses ( ×10 5/kg) (%) (%) >500/ mL >1000/ mL >20,000/ mL >50,000/ mL (days) (days)
101 SU G-CSF 3 006.9 099.0 94.3 12 12 31 46 No A&FFP (940)
102 SU G-CSF 3 005.5 098.3 95.0 11 13 18 36 Yes (371) A (918
103 SU G-CSF 2 010.8 098.6 92.2 10 13 13 17 No A&FFP (818)
104 SU G-CSF 2 037.5 098.6 95.7 10 10 12 14 No A&FFP (807)
105 SU G-CSF 2 009.2 097.0 96.3 10 10 12 15 No A&FFP (772)
107 SU G-CSF 2 016.1 099.9 97.0 09 11 13 15 Yes (512) E (733)
110 SU G-CSF 3 007.8 098.4 95.8 09 10 42 47 Yes (366) A (686)
112 SU G-CSF 2 010.7 098.1 95.6 10 12 14 16 No A&FFP (674)
113 SU G-CSF 2 008.1 097.9 94.2 10 16 14 14 No E (133)
114 SU G-CSF 3 007.1 099.3 91.1 10 10 12 17 No A&FFP (561)
203 DE G-CSF 4 004.7 096.5 92.6 15 17 28 37 Yes (199) E (564)
205 DE G-CSF 2 004.7 098.7 97.4 15 15 14 22 No E (530)
116 SU CY+G 2 163.1 097.9 96.4 08 08 09 11 Yes (466) A (607)
117 SU CY+G 2 011.8 098.9 94.9 10 10 42 49 No A&FFP (555)
119 SU CY+G 2 031.6 099.4 94.0 09 09 12 14 Yes (191) A (520)
120 SU CY+G 3 008.0 098.6 95.7 11 11 15 21 No A&FFP (513)
121 SU CY+G 2 057.2 100.0 96.0 09 11 12 12 Yes (233) A (520)
206 DE CY+G 2 037.8 098.1 95.6 12 12 12 12 Yes (514) A (564)
207 DE CY+G 2 048.6 099.2 98.3 NA 16 18 NA Yes (138) E (185)
208 DE CY+G 2 027.9 099.0 94.4 11 11 13 19 Yes (441) A (501)
212 DE CY+G 2 031.9 097.8 93.5 10 10 12 18 Yes (183) E (325)
213 DE CY+G 2 052.9 099.0 93.9 09 10 12 12 No A&FFP (436)
Median 2 011.3 098.6 95.3 10 11 14 17
Range 2-4 04.7-163.1 096.5-100 91.1-98.3 8-15 8-17 9-42 11-49
*A indicates alive; A&FFP, alive and free from progression; CY+G, cyclophosphamide plus G-CSF; DE, Detroit; E, expired; G-CSF, granulocyte colony-stimu-
lating factor; NA, not available; SU, Stanford University.
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91.1%-98.3%). The median yield of Thy-1+ cells after isola-
tion was 25.5% (range, 1.4%-58.5%), and median viability
was 98.6% (range, 96.5%-100%). Sixteen patients achieved
an adequate stem cell dose with 2 apheresis collections. Five
patients re q u i red 3 apheresis collections, and 1 patient
re q u i red 4 collections to achieve an adequate CD34+T h y - 1+
cell dose after selection. All transplantation patients re c e i v e d
the high-dose therapy regimen containing cisplatin,
cyclophosphamide, and carmustine [37]. A median of 11.3 ×
1 05 c ry o p re s e rved CD34+T h y - 1+ cells per kilogram were
infused (range, 4.7-163.1 × 1 05 cells per kilogram). No toxic-
ity was observed after infusion of the sorted cells.
Hematopoietic Cell Reconstitution
Neutrophil recovery was rapid, with an ANC >500/µL
achieved in a median of 10 days (range, 8-15 days) and
an ANC >1000 achieved in a median of 11 days (range,
8-17 days) (see Table 2). Platelet re c o v e ry was also rapid,
with an untransfused platelet count >20,000/µL occurr i n g
in a median of 14 days (range, 9-42 days) and a platelet
count >50,000/µL occurring in a median of 17 days (range,
11-49 days). One patient who did not achieve a platelet
count of >50,000/µL suffered an early relapse and died on
day 185. Over the stem cell dose range studied, there was no
relationship between CD34+Thy-1+ cell dose and neut ro p h i l
engraftment (defined as an ANC >500/µL) (Figure 1 ) .
Because neutrophil engraftment occurred in all patients
within 15 days, limiting doses of stem cells are below 4 × 105
C D 3 4+T h y - 1+ per kilogram. There was no re l a t i o n s h i p
between stem cell dose and platelet re c o v e ry in those
patients who received >8 × 105 CD34+Thy-1+ cells per kilo-
gram, whereas those patients who received <8 × 1 05
CD34+Thy-1+ cells per kilogram experienced modest delays
in platelet recovery (Figure 1). 
The transplantation pro c e d u re was generally well toler-
ated, with patients experiencing the usual complications of
nausea, vomiting, diarrhea, and fever. Patients received a
median of 8 units of packed red blood cells (range, 3-16 units)
and 3 transfusions of platelets (range, 1-33 transfusions). 
I m m une Reconstitution and Inf e c t i o n s
T-cell reconstitution is shown in Table 3. CD3+ T cells
re c o v e red to a significant degree by 28 days after transplanta-
tion but were primarily composed of CD8+ T cells. CD4+
T-cell re c o v e ry was slow, with a median of only 50 CD4+
c e l l s /µL (range, 23-161/µL) achieved by day 100. This was
not associated with a higher incidence of infectious complica-
tions. Four patients (patients no. 103, 110, 203, and 208)
developed bacteremia within the first 30 days; all re c o v e re d
with appropriate antibiotic therapy. One patient (patient no.
107) developed a urinary tract infection, also successfully
t reated with antibiotics. Two patients (patients no. 110 and
207) developed fungemia, both as a result of infection with
Candida albicans, and were successfully treated with antifungal
agents. Four patients developed viral infections. One patient
(patient no. 107) developed cytomegalovirus (CMV) vire m i a ,
which was treated successfully with ganciclovir. Two patients
(patients no. 208 and 213) developed dermatomal herpes
z o s t e r, and one patient (patient no. 212) developed ro t a v i ru s
e n t e rocolitis. There were no infection-related deaths.
A d v erse Reactions
Nine patients (41%) developed interstitial pneumonitis
related to carmustine toxicity. All patients responded to
treatment with corticosteroids, except for 1 patient (patient
no. 113), who died on day 133 as a result of complications of
re s p i r a t o ry failure. Three patients had a relapse of pneu-
monitis upon tapering of the corticosteroids but responded
to a second treatment course of steroids. In addition to these
9 patients who developed carmustine-induced interstitial
pneumonitis, 4 patients developed severe adverse re a c t i o n s
that were thought to be related to the treatment pro t o c o l .
One patient (patient no. 205) developed a cerebellar syn-
d rome of uncertain etiology thought to be related to the
high-dose regimen and eventually died of neurologic com-
plications on day 530. She did not have any clinical evidence
of metastatic disease. One patient (patient no. 119) devel-
oped clinically significant hemorrhagic cystitis, and 2
patients (patients no. 103 and 207) developed deep venous
thromboses related to central venous catheters. 
In the entire group of 22 patients who underwent high-
dose therapy and transplantation, there were no deaths
within the first 100 days. Two subsequent deaths (9.1%)
were thought to be related to treatment, as discussed above.
Tumor Cell Contamination and Depletion
A sensitive immunofluorescence assay capable of
detecting a single positive cell in 106 n o rmal cells was uti-
lized to detect minimal residual disease. Bone marrow eval-
uations were perf o rmed on all patients being considered for
the study. Of 30 samples evaluated, 11 samples (36.7%)
tested positive for cytokeratin-staining cells whose mor-
phology was consistent with metastatic breast cancer. The
number of cytokeratin-positive cells varied in fre q u e n c y
f rom 1/30,855 to 1/693,386. Intere s t i n g l y, 2 patients were
positive for CD34 expression on cytokeratin-positive cells
in the bone marrow and were excluded from part i c i p a t i o n
in the pro t o c o l .
I m m u n o f l u o rescent assessment of cytokeratin-positive
cells was perf o rmed on a sample derived from all aphere s i s
p roducts after CD34+ cell selection with the Isolex device
and after CD34+T h y - 1+ selection by flow cytometry. Pro d-
ucts from 25 patients were evaluated, and products fro m
16 of these patients were uniformly negative for cytoker-
atin-positive cells. Nine patients (36%) had at least 1 posi-
tive product either in an apheresis collection or after
C D 3 4+ cell selection with the Isolex device. Intere s t i n g l y, 8
of these patients with cytokeratin-positive products had
been mobilized with G-CSF (8 of 15 or 53%); only 1
Table 3. T-Cell Reconstitution After Transplantation With Purified
CD34+Thy-1+ Stem Cells* 
Day CD3 CD4 CD8
14 120 (10-3650) 050 (9-467) 0047 (1-3223)
28 650 (70-7450) 113 (33-580) 1034 (34-6890)
60 470 (230-1087) 088 (18-225) 0441 (200-888)
100 580 (60-1380) 050 (23-161) 0493 (23-1,002)
*Data are presented as median (range) number of cells of defined phenotype
per microliter. 
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patient with a positive product had been mobilized with
cyclophosphamide plus G-CSF (1 of 10 or 10%; P = .04).
T h ree of these patients (patients no. 111, 115, and 201) did
not proceed to high-dose therapy and transplantation
because of either inadequate CD34+T h y - 1+ cell dose or
p ro g ressive disease before the preparative regimen was
instituted. One patient (patient no. 102) had cytokeratin-
positive cells in all 3 apheresis products, at a fre q u e n c y
ranging from 1/72,048 to 1/299,459. Unfort u n a t e l y, in this
patient there were insufficient cells for minimal re s i d u a l
dose (MRD) analysis after CD34+ cell selection and cell
s o rting. In 5 patients (patients no. 103, 104, 105, 205, and
206), cytokeratin-positive cells were identified in 1 of the
a p h e resis collections at a frequency ranging from 1/84,732
to 1/783,146. In all 6 of these products, no tumor cells
w e re detected after CD34+ cell selection and CD34+
T h y-1+ stem cell sorting. Intere s t i n g l y, in 2 additional
patients (patients no. 112 and 114), cytokeratin-positive
cells, at frequencies ranging from 1/36,936 to 1/85,597,
w e re detected with the Isolex device after CD34+ c e l l
selection. These cytokeratin-positive cell s were not
detected in the unprocessed PBPC collections. In all 3 of
these products from these 2 patients, cells analyzed after
C D 3 4+T h y - 1+ stem cell sorting did not contain detectable
cytokeratin-positive cells. Of the evaluable stem cell pro d-
ucts re t u rned to the 22 patients (ie, the products that had
adequate CD34+T h y - 1+ cell numbers for analysis), all were
negative for cytokeratin-positive cells.
Patient F o l l ow - u p
After a maximum follow-up of 2.5 years, 16 of the
22 evaluable patients (73%) were alive. Nine patients (41%)
were free from progressive breast cancer (Table 2 and Fig-
ure 2), and 11 (50%) had relapsed; 2 patients (9%) had died
of transplantation-related complications, as described ear-
lier. The median time of freedom from disease progression
(FFP) was approximately 500 days; median overall surv i v a l
(OS) has not yet been reached. 
DISCUSSION
The primary objective of this study was to determ i n e
the feasibility and safety of autologous transplantation utiliz-
ing purified CD34+T h y - 1+ HSCs after high-dose therapy
for metastatic breast cancer. This is the first re p o rt of the
use of highly purified HSCs, which were free of detectable
tumor contamination and provided rapid and sustained
hematopoietic engraftment, in patients with this disease. In
other studies, performed in patients with multiple myeloma,
the purified stem cells were rendered free of detectable con-
taminating myeloma cells and resulted in engraftment; how-
ever, engraftment delays were noted in one report [38-40].
In pursuing the clinical application of CD34+T h y - 1+ c e l l s
isolated by high-speed cell sorting, there are both practical
and theoretical issues concerning the feasibility of isolating
s u fficient numbers of cells and whether these cells will
engraft in a timely fashion after infusion. To obtain suff i-
cient numbers of CD34+T h y - 1+ cells, it was necessary to
begin with mobilized PBPCs. Two successive strategies were
used for mobilization: high-dose G-CSF alone and combi-
nation therapy with cyclophosphamide and standard dose
G - C S F. Three of 15 patients (20%) treated with high-dose
G-CSF alone did not achieve an adequate stem cell dose as a
result of poor mobilization, compared with 1 of 13 (7.7%)
patients who received both cyclophosphamide and G-CSF.
T h e re f o re, the majority of patients (85.7%) did have ade-
quate collections that allowed for extensive manipulation
and isolation of CD34+T h y - 1+ stem cells. The addition of
other growth factors (eg, stem cell factor) may result in
i m p roved mobilization [41]. Selection of patients who had
never received or had had limited exposure to cytotoxic
chemotherapy might also reduce the frequency of inade-
quate HSC collections.
After high-dose therapy, the purified CD34+T h y - 1+ c e l l s
w e re used as the sole source of the graft. Considerable debate
has centered on the source of cells re q u i red for rapid and
sustained hematopoietic engraftment. With the use of puri-
fied HSCs, there has been concern that hematopoietic
Figure 2. Duration of freedom from disease progression and overall survival for 22 patients undergoing high-dose therapy and transplantation with purified
CD34+Thy-1+ hematopoietic stem cells.
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engraftment would be delayed. However, in murine models,
highly enriched populations of HSCs alone are capable of
engrafting lethally irradiated animals with cells whose
kinetics are identical to those of intact bone marrow [25].
In this study, engraftment was prompt, with neutro p h i l
re c o v e ry defined as the days re q u i red to reach an ANC
> 5 0 0 /µL and >1,000/µL, a level similar to that achieved
with unselected mobilized peripheral blood. No relationship
was observed between CD34+T h y - 1+ stem cell dose and
n e u t rophil re c o v e ry over the range of cell doses infused
(4.7 to 163 × 105 cells per kilogram). Platelet recovery was
also rapid, but there did appear to be a modest delay in
platelet re c o v e ry in those patients who received <8 × 1 05
C D 3 4+T h y - 1+ stem cells per kilogram, something that has
also been observed in patients with multiple myeloma [40].
No toxicity was associated with infusion of the purified
C D 3 4+T h y - 1+ cells. It is conceivable that doses of C D 3 4+
T h y-1+ stem cells much less than 4 × 1 05 C D 3 4+T h y -1+ cells
per kilogram might allow for engraftment, albeit delayed, as
predicted by studies with murine HSCs in which the mini-
mum radioprotective dose was 5 × 103 HSCs per kilogram
and the minimum dose for rapid hematopoietic engraftment
was 2.5 × 1 05 HSCs per kilogram [24].
A significant concern with the use of purified stem cells
has centered on the potential for delayed lymphocyte re c o v-
e ry and the risk of infection. In this study, T-cell re c o n s t i t u-
tion occurred relatively rapidly with the majority of patients
having CD3 cell numbers >500/µL by 28 days after trans-
plantation. However, the majority of these T cells were
C D 8+, and CD4+ cell re c o v e ry was indeed slow, with a
median of only 50 CD4+ cells per µL by day 100. This appar-
ent delay in CD4+ cell re c o v e ry has been observed after trans-
plantation with highly purified populations of CD34+ cells or
C D 3 4+T h y - 1+ cells in other studies [40,42]. In this study of
patients with metastatic breast cancer, there were re l a t i v e l y
few unexpected infectious episodes, except for 1 patient who
developed CMV viremia and responded to treatment with
g a n c i c l o v i r. There was no infection-related mort a l i t y. 
A secondary objective of the study was to assess the
potential of CD34+T h y - 1+ stem cell selection in re d u c i n g
tumor burden. In this group of patients with metastatic
breast cancer, 9 of 25 evaluated patients (36%) had identifi-
able cytokeratin-positive cells in at least 1 apheresis collec-
tion. This rate of tumor cell contamination is similar to that
observed in other studies of patients with metastatic breast
cancer undergoing high-dose therapy [43-45]. Interestingly,
8 of these 9 patients were mobilized with G-CSF alone,
w h e reas only 1 patient mobilized with cyclophosphamide
and G-CSF had detectable tumor cells in her products. This
o b s e rvation differs from that in a previously published
report in which no differences in tumor cell contamination
w e re observed between patients mobilized with G-CSF
alone and those mobilized with cyclophosphamide and G-
CSF [45]. The relatively small number of patients included
in the current study may explain this discrepancy. 
All apheresis products were successfully depleted of
detectable breast cancer cells by CD34+T h y - 1+ s e l e c t i o n .
The immunofluorescence assay used i s capable of
d e t e c ting a single cytokeratin-positive cell in approximately
1 06 negative cells. However, this number of cells was not
always available for screening after high-speed cell sorting,
which reduced the sensitivity of the assay. Interestingly, in 2
patients, cytokeratin-positive cells were detectable only after
CD34+ cell selection; these were successfully removed after
CD34+Thy-1+ cell selection. Excellent tumor cell reduction
has also been observed after CD34+Thy-1+ stem cell isola-
tion in patients with multiple myeloma [38,40].
No patient developed late graft failure or required infu-
sion of unmanipulated backup cells. This study was too
small to evaluate the effects of CD34+T h y - 1+ stem cell
selection on FFP or OS, but the results obtained are favor-
able, especially considering the high-risk patient population
that was studied. There were no transplantation-re l a t e d
deaths within the first 100 days, and the majority of treat-
ment failures, as expected, were a result of relapse. 
In summary, this study demonstrates that isolation of
C D 3 4+T h y - 1+ stem cells by high-speed cell sorting in
patients with metastatic breast cancer is feasible and re s u l t s
in rapid hematopoietic engraftment, especially when >8 × 1 05
C D 3 4+T h y - 1+ cells per kilogram are infused. In addition,
these data further demonstrate that this selected population
of cells alone is fully capable of trilineage hematopoietic
reconstitution after high-dose therapy. Excellent tumor cell
depletion was achieved in those patients with detectable
tumor cells in their cellular products. Additional studies are
re q u i red to determine the clinical impact of infusing purifie d
hematopoietic stem cells. Clearly this approach is technically
challenging, yet these pilot data demonstrate the feasibility
of isolating adequate numbers of purified stem cells for clini-
cal use and are critical to further exploration of highly
p u r ified stem cell populations in other clinical settings of
autologous and allogeneic transplantation. 
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